Bladder Carcinoma
40
9
13
10
Key Insights
Highlights
Success Rate
53% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
22.5%
9 terminated out of 40 trials
52.6%
-33.9% vs benchmark
10%
4 trials in Phase 3/4
80%
8 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (40)
The Vanguard Study: Testing a New Way to Screen for Cancer
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
Bladder Bank (a Prospective Banking Study)
Exploration of HRQOL and Urinary Outcomes Following Partial Cystectomy
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
PET-imaging of Two Vartumabs in Patients With Solid Tumors
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy
Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics
PUBMIC (Prophylactic Use of Biologic Mesh in Ileal Conduit)
Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device